FDA enforcement record
Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)
Published Apr 8, 2022 · Public FDA record · CofixRx, LLC
- Recipient: CofixRx, LLC
- Date: Apr 8, 2022
Why this record matters
FDA warning letters are public enforcement actions: they flag significant violations, often precede import alerts or deeper enforcement, and are read closely by customers, suppliers and competitors. For how to interpret one — and how a Form 483 escalates into a letter — see our 483 vs warning letter guide and the 15-day response playbook.
Get new FDA warning letters the day they publish
Daily Telegram or email briefs — device, drug and food streams. Free tier available.
Latest letters
- CGMP/Dietary Supplement/Adulterated/Misbranded · Apr 28, 2026
- CGMP/Finished Pharmaceuticals/Adulterated · Apr 28, 2026
- CGMP/Finished Pharmaceuticals/Adulterated · Apr 28, 2026
- Foreign Supplier Verification Program (FSVP) · Apr 28, 2026
- Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded · Apr 23, 2026
- Notice of Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet · Apr 14, 2026